← All stories
Markets
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robust, and durable efficacy Topline results from Phase 3 GAD studies of DT120 ODT in generalized anxiety dis…
Covered by 1 outlet
All coverage · 1 article